Angela Rose Brannon

Tumor and ctDNA concordance of actionable alterations in metastatic breast cancer

As biomarker-driven therapies are available for hormone receptor-positive (HR+) metastatic breast cancer (MBC), identification of actionable alterations is critical for determining the optimal therapy. Both tissue and plasma ctDNA next-generation sequencing (NGS) assays can revea...